Two novel benzopyrroloxazine-based selective GPER antagonists, PBX1 and PBX2, inhibit GPER-dependent signaling in breast cancer cells and cancer-associated fibroblasts (CAFs), but require further validation in preclinical and clinical trials (295). The gene discussed is GPER1; the disease is breast carcinoma.